Cyclic nucleotides as targets for drug design
- PMID: 24326
- DOI: 10.1016/b978-0-12-013312-3.50004-2
Cyclic nucleotides as targets for drug design
Similar articles
-
Second messenger system in neoplasia.Oncology. 1974;30(1):43-80. doi: 10.1159/000224940. Oncology. 1974. PMID: 4155059 Review. No abstract available.
-
Compartmentalization of cyclic nucleotide-mediated hormone action.Annu Rev Pharmacol Toxicol. 1978;18:431-59. doi: 10.1146/annurev.pa.18.040178.002243. Annu Rev Pharmacol Toxicol. 1978. PMID: 25610 Review. No abstract available.
-
Levels of cyclic nucleotides in mouse regional brain following 300 ms microwave inactivation.J Neurochem. 1977 Apr;28(4):759-63. doi: 10.1111/j.1471-4159.1977.tb10624.x. J Neurochem. 1977. PMID: 19560 No abstract available.
-
Cyclic nucleotides as regulators of proliferation and differentiated cell function.J Cyclic Nucleotide Res. 1976 Jul-AUG;2(4):189-204. J Cyclic Nucleotide Res. 1976. PMID: 9428 No abstract available.
-
Pharmacological control of the synthesis and metabolism of cyclic nucleotides.Adv Pharmacol Chemother. 1977;14:189-283. doi: 10.1016/s1054-3589(08)60189-1. Adv Pharmacol Chemother. 1977. PMID: 18912 Review. No abstract available.
Cited by
-
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.Front Pharmacol. 2022 Nov 24;13:1057083. doi: 10.3389/fphar.2022.1057083. eCollection 2022. Front Pharmacol. 2022. PMID: 36506513 Free PMC article. Review.
-
Phosphodiesterase Inhibition in the Treatment of Preeclampsia: What Is New?Curr Hypertens Rep. 2018 Jul 26;20(10):83. doi: 10.1007/s11906-018-0883-x. Curr Hypertens Rep. 2018. PMID: 30051151 Review.
-
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.Br J Pharmacol. 2012 Mar;165(5):1288-305. doi: 10.1111/j.1476-5381.2011.01729.x. Br J Pharmacol. 2012. PMID: 22014080 Free PMC article. Review.